# Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma

> **NCT00989664** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 60 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **BIOLOGICAL:** Tositumomab and Iodine I 131 Tositumomab

## Key facts

- **NCT ID:** NCT00989664
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-11
- **Primary completion:** 2004-01
- **Final completion:** 2008-09
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989664, "Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00989664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*